Metoprolol succinate (tablet): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 1: Line 1:
{|class="infobox" style="position: fixed; top: 180px; right: 20px; margin: 0 0 0 0; border: 0; float: right; width: 15%; background: #104E8B; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0";
{{DrugProjectFormSinglePage
|-
|genericName=generic name
! style="font-size: 80%; padding: 0 5px; background: #104E8B;" | [[{{PAGENAME}}|{{fontcolor|#F8F8FF|{{PAGENAME}}®}}]]
|aOrAn=a
|-
|drugClass=Adrenergic receptor agonist
! style="font-size: 80%; padding: 0 5px; background: #000000; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|Black Box Warning}}]]
|indication=a list of indications, separated by commas.
|-
|hasBlackBoxWarning=Yes
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adult Indications and Dosage|{{fontcolor|#F8F8FF|Adult Indications and Dosage}}]]
|adverseReactions=a list of adverse reactions, separated by commas.
|-
|blackBoxWarningTitle=Warning Title
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pediatric Indications and Dosage|{{fontcolor|#F8F8FF|Pediatric Indications and Dosage}}]]
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|-
|fdaLIADAdult======Condition 1=====
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Contraindications|{{fontcolor|#F8F8FF|Contraindications}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Warnings|{{fontcolor|#F8F8FF|Warnings}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adverse Reactions|{{fontcolor|#F8F8FF|Adverse Reactions}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Drug Interactions|{{fontcolor|#F8F8FF|Drug Interactions}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Use in Specific Populations|{{fontcolor|#F8F8FF|Use in Specific Populations}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Administration and Monitoring|{{fontcolor|#F8F8FF|Administration and Monitoring}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#IV Compatibility|{{fontcolor|#F8F8FF|IV Compatibility}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Overdosage|{{fontcolor|#F8F8FF|Overdosage}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pharmacology|{{fontcolor|#F8F8FF|Pharmacology}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Clinical Studies|{{fontcolor|#F8F8FF|Clinical Studies}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#How Supplied|{{fontcolor|#F8F8FF|How Supplied}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Images|{{fontcolor|#F8F8FF|Images}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Patient Information|{{fontcolor|#F8F8FF|Patient information}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Precautions with Alcohol|{{fontcolor|#F8F8FF|Precautions with Alcohol}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Brand Names|{{fontcolor|#F8F8FF|Brand Names}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Look-Alike Drug Names|{{fontcolor|#F8F8FF|Look-Alike Drug Names}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm {{fontcolor|#F8F8FF|Drug Shortage Status}}]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price {{fontcolor|#F8F8FF|Price}}]
|-
|}
<div style="width: 80%">
__NOTOC__
{{Main|Metoprolol}}
 
{{CMG}}
 
{{SB}}
 
==Disclaimer==
 
'''''WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment.  WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer [[wikidoc:General_disclaimer|{{fontcolor|#FF0000|here}}]].'''''
 
==<span style="color:#FF0000; background:#000000;">Black Box Warning</span>==
 
FDA Package Insert for {{PAGENAME}} contains no information regarding ''Black Box Warning''.
 
{| style="border: 3px solid #696969;"
| style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" |
<center>
<font color="#F8F8FF" style="font-weight: bold;">WARNING</font>
</center>
 
<center>
<font color="#F8F8FF" size="1" style="font-style: italic;">See full prescribing information for complete boxed warning.</font>
</center>
 
<font color="#F8F8FF" style="font-weight: bold;">
''{{fontcolor|#FF0000|Condition Name:}}'' (Content)
</font>
|}
 
==Overview==
 
{{PAGENAME}} is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown <span style="background:#000000;">'''[[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|here}}]]'''</span>. Common adverse reactions include _______.
 
==Adult Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Adult)===
 
=====Condition 1=====


* Dosing Information
* Dosing Information
Line 96: Line 19:


:* (Dosage)
:* (Dosage)
 
|offLabelAdultGuideSupport======Condition 1=====
===Off-Label Use and Dosage (Adult)===
 
====Guideline-Supported Use====
 
=====Condition 1=====


* Developed by: (Organisation)
* Developed by: (Organisation)
Line 124: Line 42:


:* (Dosage)
:* (Dosage)
 
|offLabelAdultNoGuideSupport======Condition 1=====
====Non–Guideline-Supported Use====
 
=====Condition 1=====


* Dosing Information
* Dosing Information
Line 144: Line 59:


:* (Dosage)
:* (Dosage)
 
|fdaLIADPed======Condition 1=====
==Pediatric Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Pediatric)===
 
=====Condition 1=====


* Dosing Information
* Dosing Information
Line 160: Line 70:


:* (Dosage)
:* (Dosage)
 
|offLabelPedGuideSupport======Condition 1=====
===Off-Label Use and Dosage (Pediatric)===
 
====Guideline-Supported Use====
 
=====Condition 1=====


* Developed by: (Organisation)
* Developed by: (Organisation)
Line 188: Line 93:


:* (Dosage)
:* (Dosage)
 
|offLabelPedNoGuideSupport======Condition 1=====
====Non–Guideline-Supported Use====
 
=====Condition 1=====


* Dosing Information
* Dosing Information
Line 208: Line 110:


:* (Dosage)
:* (Dosage)
 
|contraindications=* Condition 1
==Contraindications==
 
* Condition 1
* Condition 2
* Condition 2
* Condition 3
* Condition 3
* Condition 4
* Condition 4
* Condition 5
* Condition 5
 
|warnings======Conidition 1=====
==Warnings==
 
=====Conidition 1=====
 
(Description)
 
=====Conidition 2=====


(Description)
(Description)


=====Conidition 3=====
|clinicalTrials=======Central Nervous System======
 
(Description)
 
==Adverse Reactions==
 
===Clinical Trials Experience===
 
=====Condition 1=====
 
======Central Nervous System======


: (list/description of adverse reactions)
: (list/description of adverse reactions)
Line 286: Line 168:


: (list/description of adverse reactions)
: (list/description of adverse reactions)
 
|postmarketing=(Description)
===Postmarketing Experience===
|drugInteractions=* Drug 1
 
* Drug 2
(Description)
* Drug 3
 
* Drug 4
==Drug Interactions==
* Drug 5


=====Drug 1=====
=====Drug 1=====
Line 312: Line 194:


(Description)
(Description)
|useInPregnancyFDA=(Description)
|useInPregnancyAUS=(Description)
|useInLaborDelivery=(Description)
|useInNursing=(Description)
|useInPed=(Description)
|useInGeri=(Description)
|useInGender=(Description)
|useInRace=(Description)
|useInRenalImpair=(Description)
|useInHepaticImpair=(Description)
|useInReproPotential=(Description)
|useInImmunocomp=(Description)
|othersTitle=Others
|useInOthers=(Description)


==Use in Specific Populations==
|administration=(Oral/Intravenous/etc)
 
|monitoring======Condition 1=====
====Pregnancy====
 
* '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]: X'''
 
* '''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]: {{PAGENAME}} is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.'''
 
(Description)
 
====Labor and Delivery====
 
(Description)
 
====Nursing Mothers====
 
(Description)
 
====Pediatric Use====
 
(Description)
 
====Geriatric Use====
 
(Description)
 
====Gender====
 
(Description)
 
====Race====
 
(Description)
 
====Renal Impairment====
 
(Description)
 
====Hepatic Impairment====
 
(Description)
 
====Carcinogenesis, Mutagenesis, Impairment of Fertility====
 
(Description)
 
====Immunocompromised Patients====
 
(Description)
 
====Miscellaneous====
 
(Description)
 
==Administration and Monitoring==
 
====Administration====
 
(Oral/Intravenous/etc)
 
====Monitoring====
 
=====Condition 1=====


(Description regarding monitoring, from ''Warnings'' section)
(Description regarding monitoring, from ''Warnings'' section)
Line 386: Line 221:


(Description regarding monitoring, from ''Warnings'' section)
(Description regarding monitoring, from ''Warnings'' section)
 
|IVCompat====Solution===
==IV Compatibility==
 
===Solution===


====Compatible====
====Compatible====
Line 518: Line 350:
* Solution 2
* Solution 2
* Solution 3
* Solution 3
 
|overdose====Acute Overdose===
==Overdosage==
 
===Acute Overdose===


====Signs and Symptoms====
====Signs and Symptoms====
Line 540: Line 369:


(Description)
(Description)
 
|drugBox={{Drugbox2
==Pharmacology==
 
{{Drugbox2
| verifiedrevid =  
| verifiedrevid =  
| IUPAC_name =  
| IUPAC_name =  
Line 596: Line 422:
| melting_point =  
| melting_point =  
}}
}}
 
|mechAction=(Description)
===Mechanism of Action===
|structure=(Description with picture)
 
|PD=(Description)
(Description)
|PK=(Description)
 
|nonClinToxic=(Description)
===Structure===
|clinicalStudies======Condition 1=====
 
(Description with picture)
 
===Pharmacodynamics===
 
(Description)
 
===Pharmacokinetics===
 
(Description)
 
===Nonclinical Toxicology===
 
(Description)
 
==Clinical Studies==
 
=====Condition 1=====


(Description)
(Description)
Line 630: Line 438:


(Description)
(Description)
 
|howSupplied=(Description)
==How Supplied==
|fdaPatientInfo=(Patient Counseling Information)
 
|nlmPatientInfo=(Link to patient information page)
(Description)
|lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
 
* National Drug Code (NDC):
* Storage:
* Manufactured by: 
* Distributed by:
 
==Images==
 
===Drug Images===
 
{|
| [[File:PILLIMAGE.jpg|thumb|300px|<p style="text-align: left;">
'''Drug Name''':  <BR>
'''Ingredient(s)''':  <BR>
'''Imprint''':  <BR>
'''Color(s)''':  <BR>
'''Shape''':  <BR>
'''Size (mm)''':  <BR>
'''Score''':  <BR>
'''Drug Label Author''':  ]]</p>
|}
 
===Package and Label Display Panel===
 
(Package Images)
 
(Display Panel Images)
 
==Patient Information==
 
===Patient Information from FDA===
 
(Patient Counseling Information)
 
===Patient Information from NLM===
 
(Link to patient information page)
 
==Precautions with Alcohol==
 
Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
==Brand Names==
 
Brand Names®
 
==Look-Alike Drug Names==
 
* (Paired Confused Name 1a) — (Paired Confused Name 1b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
 
|drugShortage=Drug Shortage
==[http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm Drug Shortage Status]==
}}
 
==[http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price Price]==
 
==References==
 
{{reflist}}
 
</div>

Revision as of 13:25, 3 July 2014

Metoprolol succinate (tablet)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Metoprolol succinate (tablet) is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
Conidition 1

(Description)

Adverse Reactions

Clinical Trials Experience

Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): (Description)
Pregnancy Category (AUS): (Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatic Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Females of Reproductive Potential and Males

(Description)

Immunocompromised Patients

(Description)

Others

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Metoprolol succinate (tablet)
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

Storage

There is limited information regarding Metoprolol succinate (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Metoprolol succinate (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Metoprolol succinate (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

(Patient Counseling Information)

Precautions with Alcohol

Alcohol-Metoprolol succinate (tablet) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Metoprolol succinate (tablet) Brand Names in the drug label.

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Metoprolol_succinate_(tablet)&oldid=987983"